Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
Alto Neuroscience shares fell 3.1% on Thursday, a day after the company said topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 was not statistically significant on...